• Omnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France
• Full commercial launch of Omnipod 5 with Dexcom G7 integration has commenced in the U.S.
• Omnipod 5 App for iPhone begins limited market release in the U.S.

ACTON, Mass. / Jun 20, 2024 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well as the limited market release of the Omnipod 5 App for iPhone.

“Achieving these milestones demonstrates our Company’s ongoing commitment to making our life-changing diabetes technology more accessible around the world,” said Jim Hollingshead, President and Chief Executive Officer. “With our recent expansion into France, Omnipod 5 is now accessible to the majority of our European customers. The integration of Dexcom G7 and the iPhone mobile app in the U.S. enables more options for those considering Omnipod 5 for their insulin delivery.”

Omnipod 5, the #1 prescribed and #1 favorite pump¹ in the U.S., is the first tubeless AID system that communicates with a continuous glucose monitor (CGM) and proactively corrects for highs and protects against lows, day and night. The waterproof² Pod and mobile app control have been designed with the customer in mind aiming to deliver exceptional ease of use. Omnipod 5 has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in hypoglycemia.^3,4

Omnipod 5 is Now Available in France

Omnipod 5 is now available in France to people with type 1 diabetes, ages two years or older, and is compatible with the Dexcom G6 CGM. Omnipod 5 recently received reimbursement status from the French National Authority for Health (Haute Autorité de Santé or HAS), making the system accessible to eligible people with type 1 diabetes.

“Omnipod 5 has already had a huge impact on health outcomes for those with type 1 diabetes. Today, we celebrate the introduction of Omnipod 5 in France, which we know has been eagerly anticipated,” said Patrick Crannell, Senior Vice President and International General Manager. “The results of our studies demonstrate that Omnipod 5 improves quality of life and represents a significant advancement in diabetes management.”

Omnipod 5 with Dexcom G7 (U.S.)

Insulet has begun the full commercial launch of Omnipod 5 with Dexcom G7 sensor integration in the U.S. Omnipod 5 is the only tubeless automated insulin delivery system that connects with both Dexcom G6 and G7 sensors, providing more choice for people with type 1 diabetes.

New Omnipod 5 customers will receive the updated starter kit, which includes a new Pod compatible with both Dexcom G6 and Dexcom G7 and a Controller now featuring user-selectable Dexcom CGM options to connect to the Pod. Insulet is in the process of communicating to existing Omnipod 5 users in the U.S. that their free remote software update is anticipated to be available the week of July 29.

Omnipod 5 App for iPhone (U.S.)

Insulet recently started a limited market release of its highly anticipated Omnipod 5 App for iPhone in the U.S. Insulet is the first and only company to offer a tubeless AID system with full control from a compatible Android or iOS smartphone.

The Omnipod 5 App for iPhone will launch first with Dexcom G6 integration. Insulet will communicate broadly to the diabetes community when the Omnipod 5 App for iPhone is available on the App Store. The Omnipod 5 App for iPhone with Dexcom G7 will follow in the future.

To stay informed of Insulet’s progress with future innovation, visit Omnipod.com/innovation. You may also speak with a member of the Insulet team in the Exhibit Hall at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida, taking place Friday, June 21 through Monday, June 24. A full schedule of events and presentations is listed on Omnipod.com.

About Insulet Corporation

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.